Medtronic steams ahead with carotid stenting trial:
This article was originally published in Clinica
Executive Summary
Medtronic has begun the third in a series of studies to evaluate its system of devices to treat blockages in the carotid arteries that can lead to ischaemic strokes. The MAVErIC III clinical trial will gather data for submission to US regulatory authorities to evaluate the safety and efficacy of a combination of the firm's Interceptor PLUS carotid filter system and Exponent self-expanding carotid stent. It has already enrolled the first patient and will include 413 high-risk patients at 35 centres in North America. According to the American Heart Association, carotid stenting is expected to grow from about 17,000 procedures this year to more than 125,000 worldwide in 2008, Medtronic said.
You may also be interested in...
Dr Reddy’s Knocked Back On Rituximab In US
Dr Reddy’s has received a complete response letter from the US FDA, knocking back its proposed rituximab biosimilar rival to Rituxan.
Sandoz And Samsung Celebrate Stelara Rival’s EU Approval
Sandoz and Samsung Bioepis have received final European Commission approval for their partnered Pyzchiva biosimilar rival to Stelara. But with European competition on ustekinumab due to kick off in just a matter of months, further applicants are also waiting in the wings.
Second EU MDR Notified Body Designated In France
Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.